Change: offered +33% / raised +268% / placed 92%
Immunome upped its financing to $800,000 from $600,000 after receiving new commitments. A total of twenty-two additional backers invested $535,000 in the company’s offering. The prior information, filed on March 3rd, stated one investor had committed $200,000. Immunome’s offering has $65,000 left up for subscription. The offering’s expected net proceeds amount to $720,000, excluding $80,000 earmarked for the payment of officers’ salaries. The subscription is structured to close once the 8% left is fully subscribed or in almost a year at the latest. The company closed four unregistered private placements which raised an estimated $3.88 million. The company is backed by BioAdvance Greenhouse Fund which provides seed and pre-seed capital for companies developing new technologies to improve human health.
The company works toward creating new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. New targets are needed to create antibody drugs with better activity against diverse tumor types, less resistance, fewer off-target effects, and superior survival outcomes.
The company is headquartered in Wynnewood PA. Immunome kept its revenues undisclosed.
The executive team includes Jane H Hollingsworth, Joan Lau, Joel H Sussman and Scott K Dessain.
The board of directors includes Gregory Harriman, I Wistar Morris and Michael D Widlitz.
The company has raised an estimated total of $4.62 million via private unregistered security offerings.
Status: Intermediary close
Amount offered: $800,000
Amount placed: $735,000
First sale: 02-19-2014
Data as of: 03-19-2014